Results 1 to 10 of about 196,511 (287)

Editorial: Angiogenesis and Angiogenesis Inhibitors in Oral Cancer [PDF]

Frontiers in Oral Health, 2021
Non peer ...
Abdelhakim Salem, Abdelhakim Salem, Elin Hadler-Olsen, Elin Hadler-Olsen, Ahmed Al-Samadi, Ahmed Al-Samadi   +5 more
doaj   +6 more sources

Angiogenesis Inhibitors for Head and Neck Squamous Cell Carcinoma Treatment: Is There Still Hope? [PDF]

Frontiers in Oncology, 2021
BackgroundHead and neck squamous cell carcinoma (HNSCC) carries poor survival outcomes despite recent progress in cancer treatment in general. Angiogenesis is crucial for tumour survival and progression.
Aini Hyytiäinen, Aini Hyytiäinen, Wafa Wahbi, Wafa Wahbi, Otto Väyrynen, Kauko Saarilahti, Peeter Karihtala, Tuula Salo, Tuula Salo, Tuula Salo, Tuula Salo, Tuula Salo, Ahmed Al-Samadi, Ahmed Al-Samadi   +13 more
doaj   +2 more sources

The efficacy and safety of angiogenesis inhibitors for recurrent ovarian cancer: a meta‑analysis [PDF]

Journal of Ovarian Research, 2022
Objective To investigate the efficacy and safety of angiogenesis inhibitors in the treatment of recurrent ovarian cancer (OC). Methods Electronic databases including PubMed, Web of Science, and the Cochrane Library were searched to find eligible studies ...
Chunmei Zhang, Wancheng Zhao
doaj   +2 more sources

Cardiotoxic effects of angiogenesis inhibitors. [PDF]

Clin Sci (Lond), 2021
Abstract The development of new therapies for cancer has led to dramatic improvements in survivorship. Angiogenesis inhibitors represent one such advancement, revolutionising treatment for a wide range of malignancies. However, these drugs are associated with cardiovascular toxicities which can impact optimal cancer treatment in the ...
Dobbin SJH, Petrie MC, Myles RC, Touyz RM, Lang NN.   +4 more
europepmc   +6 more sources

Endogenous inhibitors of angiogenesis [PDF]

Journal of Cell Science, 2001
In the course of embryonic development, during some normal physiological processes in the adult, such as the female reproductive cycle, and also in a variety of pathologies, including tumour growth, new blood vessels develop from the pre-existing vascular network through endothelial cell sprouting,
Christiana Ruhrberg
openalex   +6 more sources

Pathological complete response after nivolumab therapy following angiogenesis inhibitors in a patient with metastatic renal cell carcinoma [PDF]

IJU Case Reports, 2020
Introduction Nivolumab is effective for advanced renal cell carcinoma; however, reports are limited wherein nivolumab is combined with sequential therapy of angiogenesis inhibitors and metastasectomy.
Hiroki Hagimoto, Soki Kashima, Kazuki Doi, Shintaro Nakayama, Takanori Sano, Satoshi Imai, Tomihiko Yasufuku, Mototsugu Muramaki, Yuji Yamada   +8 more
doaj   +2 more sources

Efficacy and safety of EGFR-TKIs in combination with angiogenesis inhibitors as first-line therapy for advanced EGFR-mutant non-small-cell lung cancer: a systematic review and meta-analysis [PDF]

BMC Pulmonary Medicine, 2023
Background For patients with advanced non-small-cell lung cancer (NSCLC) with EGFR mutations, the suggested course of action is epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs).
Di Hu, Yan-Yan Zhou, Hong-Bo Ma, Miao-Miao Tao, Qun-Zhen Huang, Zhen-Zhou Yang, Qi Zhou   +6 more
doaj   +2 more sources

Cardiovascular Toxicity of Angiogenesis Inhibitors Among Patients With Cancer in Taiwan: A Nested Case‐Control Study [PDF]

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Research on the cardiovascular toxicity of angiogenesis inhibitors among patients with cancer in Taiwan is lacking. This observational study explored the risk of major adverse cardiovascular events (MACEs) associated with angiogenesis ...
Yen‐Chou Chen, Chun‐Yao Huang, Li‐Ming Lien, Jin‐Hua Chen, Fang‐I Hsieh   +4 more
doaj   +2 more sources

Angiogenesis Inhibitors in NSCLC. [PDF]

Int J Mol Sci, 2017
Angiogenesis is a complex biological process that plays a relevant role in sustaining the microenvironment, growth, and metastatic potential of several tumors, including non-small cell lung cancer (NSCLC). Bevacizumab was the first angiogenesis inhibitor approved for the treatment of patients with advanced NSCLC in combination with chemotherapy ...
Manzo A, Montanino A, Carillio G, Costanzo R, Sandomenico C, Normanno N, Piccirillo MC, Daniele G, Perrone F, Rocco G, Morabito A.   +10 more
europepmc   +5 more sources

The impact of angiogenesis inhibitors on survival of patients with small cell lung cancer [PDF]

Cancer Medicine, 2019
Background Small cell lung cancer (SCLC) is a highly invasive and lethal neuroendocrine tumor. Antiangiogenic drugs have been reported in the treatment of SCLC. We aimed to provide a comprehensive evaluation of the impact of angiogenic inhibitors on SCLC
Xiaoshun Shi, Xiaoying Dong, Sylvia Young, Allen Menglin Chen, Xiguang Liu, Zhouxia Zheng, Kailing Huang, Di Lu, Siyang Feng, Grant Morahan, Kaican Cai   +10 more
doaj   +2 more sources